专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110256137A1 PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY FOR EPCAM 有权
标题翻译：包含EPCAM的双重抗体的药物组合物
公开(公告)号：US20110256137A1
公开(公告)日：2011-10-20
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
IPC分类号： A61K39/395 , C07H21/00 , A61P35/00 , C12P21/02 , C12N5/10 , C12N1/00 , C07K16/28 , C12N15/63
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

2. 发明授权

US08790645B2 Pharmaceutical composition comprising a bispecific antibody for EpCAM 有权
标题翻译：包含用于EpCAM的双特异性抗体的药物组合物
公开(公告)号：US08790645B2
公开(公告)日：2014-07-29
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schütz , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00 , C07K16/30 , C07K16/28
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

3. 发明申请

US20090022738A1 Multispecific deimmunized CD3-binders 有权
标题翻译：多特异性去免疫化CD3结合物
公开(公告)号：US20090022738A1
公开(公告)日：2009-01-22
申请号：US10572740
申请日：2004-10-15
申请人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Christian Itin , Patrick Bauerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
发明人： Robert Hofmeister , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Christian Itin , Patrick Bauerle , Francis J. Carr , Anita A. Hamilton , Stephen Williams
IPC分类号： A61K39/395 , C07K16/00 , C07H21/00 , C12N15/63 , A61K35/12 , A61P39/00 , A61P37/02 , A61P35/00 , A61K31/7052 , C12N5/00 , C12P21/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/2803 , C07K16/2809 , C07K16/30 , C07K2317/24 , C07K2317/31 , C07K2317/567
摘要： The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要翻译：本发明提供了细胞毒活性CD3特异性结合构建体，其包含与人CD3特异性结合的第一结构域和来自Ig的第二结合结构域。此外，提供了编码本发明的CD3特异性结合构建体的核酸序列。本发明的其它方面是包含所述核酸序列的载体和宿主细胞，用于生产本发明构建体的方法和包含所述构建体的组合物。本发明还提供所述构建体用于制备用于治疗特定疾病的药物组合物，用于治疗特定疾病的方法和包含本发明的结合构建体的试剂盒的用途。

4. 发明授权

US07635472B2 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders 有权
标题翻译：包含用于治疗b细胞相关疾病的双特异性抗cd3抗CD19抗体构建体的药物组合物
公开(公告)号：US07635472B2
公开(公告)日：2009-12-22
申请号：US10554852
申请日：2004-05-26
申请人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
发明人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
IPC分类号： A61K39/395 , C07K16/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/622
摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3) or VH(CD3)-VL-(CD3)-VH(CD19)-VL (CD19). Processes for the production of the pharmaceutical compositions and medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are also disclosed.
摘要翻译：本发明涉及包含双特异性单链抗体构建体的药物组合物，其包含对人CD3和人CD19特异性的结合结构域，其中相应的可变重链区（VH）和相应的可变轻链区（VL）区域被布置， VH（CD19）-VL（CD19）-VH（CD3）-VL（CD3）或VH（CD3）-VL-（CD3）-VH（CD19）-VL（从N末端至C末端） CD19）。还公开了用于制备针对人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的药物组合物和医用/药物用途的方法。

5. 发明申请

US20070123479A1 Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders 有权
标题翻译：包含用于治疗b细胞相关疾病的双特异性抗cd3抗CD19抗体构建体的药物组合物
公开(公告)号：US20070123479A1
公开(公告)日：2007-05-31
申请号：US10554852
申请日：2004-05-26
申请人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
发明人： Peter Kufer , Ralf Lutterbuse , Birgit Kohleisen , Steven Zeman , Patrick Bauerle
IPC分类号： A61K39/395 , A61K48/00
CPC分类号： C07K16/2803 , A61K2039/505 , C07K2317/31 , C07K2317/34 , C07K2317/622
摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL-(CD3)-VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.
摘要翻译：本发明涉及包含双特异性单链抗体构建体的药物组合物，所述双特异性单链抗体构建体包含对人CD3和人CD19特异的结合结构域，其中相应的可变重链区（V H H H））和相应的可变轻链区域（V L L）区域从N末端到C末端按顺序排列，V H（CD19）-V （CD19）-V H（CD 3）-V L（CD 3），V H（CD 3） - （CD3）-V H（CD19）-VLL（CD19）或V H（H）（CD 3）-V L（CD 3）-V L（CD 19）-V H（CD 19）。此外，公开了用于生产所述药物组合物的方法以及对于人CD3抗原和人CD19抗原具有特异性的特异性双特异性单链抗体分子的医学/药物用途。

6. 发明申请

US20080317746A1 Anti-Il2 Antibodies 有权
标题翻译：抗Il2抗体
公开(公告)号：US20080317746A1
公开(公告)日：2008-12-25
申请号：US11916017
申请日：2006-05-31
申请人： Patrick Bauerle , John Lumsden , Stefan Pflanz , Tobias Raum , Jorg Volkland
发明人： Patrick Bauerle , John Lumsden , Stefan Pflanz , Tobias Raum , Jorg Volkland
IPC分类号： A61K39/395 , C07K16/24 , A61P9/10 , A61P35/00 , A61K48/00 , A61K31/711 , A61P37/02 , C07H21/04
CPC分类号： C07K14/55 , C07K16/246 , C07K2317/24 , C07K2317/567 , C07K2317/73 , C07K2317/76
摘要： The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interleukin-2 (IL2), wherein said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to said human IL2 prior to, during, and/or subsequent to the binding of said human IL2 to the human IL2-receptor, and wherein the light chain variable region of said humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.
摘要翻译：本发明涉及特异性结合人白细胞介素-2（IL2）的人源化单克隆抗体或其片段，其中所述人源化单克隆抗体通过在之前，期间和/或之后与所述人IL2结合而中和人IL2的活性所述人IL2与人IL2受体的结合，并且其中所述人源化单克隆抗体的轻链可变区在其第二框架区域中包含氨基酸位置42-46处的连续氨基酸序列KAPKA。

7. 发明申请

US20070122852A1 Method for identifying antigen specific b cells 审中-公开
标题翻译：鉴定抗原特异性b细胞的方法
公开(公告)号：US20070122852A1
公开(公告)日：2007-05-31
申请号：US10534788
申请日：2003-11-12
申请人： Patrick Bauerle , Patrick Hoffman , Susanne Weinberger , Roman Kischel
发明人： Patrick Bauerle , Patrick Hoffman , Susanne Weinberger , Roman Kischel
IPC分类号： C40B30/06 , C40B50/06 , C40B40/10 , G01N33/567 , C07K16/28
CPC分类号： C07K16/2818 , C07K16/4283 , C07K2317/31 , C07K2317/622 , G01N15/1456 , G01N33/542 , G01N33/56972 , G01N2015/149
摘要： The present invention relates to a method of identifying a B cell carrying a surface immunoglobulin molecule having a binding site for an antigen of interest comprising contacting a sample putatively containing said B cell with the antigen of interest wherein said antigen is labeled with a first label and with a receptor specifically binding to said surface immunoglobulin molecule wherein said receptor is labeled with a second label and wherein said first label, when being brought into a spatial proximity of between 10 and 100 Angstrom with said second label emits a detectable signal upon activation of said second label by an external source and assessing the presence of said detectable signal, wherein said presence is, in turn, indicative of the B cell carrying a surface molecule having a binding site for the antigen of interest.
摘要翻译：本发明涉及一种鉴定携带具有感兴趣的抗原结合位点的表面免疫球蛋白分子的B细胞的方法，包括将所述B细胞的推定含有的样品与感兴趣的抗原接触，其中所述抗原用第一标记标记，具有特异性结合所述表面免疫球蛋白分子的受体，其中所述受体用第二标记物标记，并且其中所述第一标记在被所述第二标记物置于10埃至100埃之间的空间接近度时，在激活所述第二标记时发射可检测信号第二标记，并评估所述可检测信号的存在，其中所述存在反过来指示携带具有感兴趣抗原结合位点的表面分子的B细胞。

8. 发明申请

US20060272037A1 Millisecond activation switch for seven-transmembrane proteins 有权
标题翻译：用于七跨膜蛋白的毫秒激活开关
公开(公告)号：US20060272037A1
公开(公告)日：2006-11-30
申请号：US10538985
申请日：2003-12-19
申请人： Patrick Bauerle
发明人： Patrick Bauerle
IPC分类号： A01K67/033 , G01N33/567 , C07H21/04 , C12P21/06 , G01N33/53 , C12N5/06 , C07K14/705
CPC分类号： G01N33/542 , C07K14/705 , G01N2333/705 , G01N2500/04 , G01N2500/10
摘要： The present invention relates to recombinant seven-trans-membrane receptor, whereby the amino terminus of said recombinant receptor is located on an extracellular side and the carboxy-terminus is located on an intracellular side of a membrane, comprising at least two detectable labels, whereby a first of said at least two detectable labels is or is located on the carboxy-terminus and whereby a second of said at least two labels is or is located on the first or third intracellular loop or whereby a first of said at least two labels is or is located on the third intracellular loop. Furthermore, nucleic acid molecules encoding said recombinant seven-transmembrane receptors are described as well as vector and host cells comprising the same. Furthermore, the present invention provides for identification and screening methods for molecules or compounds which are capable of modifying the biological end of pharmacological function of seven-transmembrane receptor proteins. Finally, diagnostic compositions comprising the compounds of the present invention as well as kits comprising said compounds are disclosed.
摘要翻译：本发明涉及重组7-跨膜受体，其中所述重组受体的氨基末端位于胞外侧，羧基末端位于膜的细胞内侧，其包含至少两个可检测标记，由此所述至少两个可检测标记中的第一个位于羧基末端或位于羧基末端，并且其中所述至少两个标记中的第二个位于或位于第一或第三细胞内环上，或由此所述至少两个标记中的第一个或位于第三细胞内环。此外，描述了编码所述重组七跨膜受体的核酸分子以及包含其的载体和宿主细胞。此外，本发明提供能够修饰七跨膜受体蛋白质的药理功能的生物学末端的分子或化合物的鉴定和筛选方法。最后，公开了包含本发明化合物的诊断组合物以及包含所述化合物的试剂盒。

9. 发明申请

US20050176028A1 Deimmunized binding molecules to CD3 审中-公开
标题翻译：去免疫结合分子与CD3
公开(公告)号：US20050176028A1
公开(公告)日：2005-08-11
申请号：US10966406
申请日：2004-10-15
申请人： Robert Hofmeister , Christian Itin , Francis Carr , Patrick Bauerle , Anita Hamilton , Stephen Williams
发明人： Robert Hofmeister , Christian Itin , Francis Carr , Patrick Bauerle , Anita Hamilton , Stephen Williams
IPC分类号： C07K16/28 , C07K16/46 , C12Q1/68 , C07H21/04 , C07K14/74 , G01N33/53 , G01N33/567
CPC分类号： C07K16/461 , A61K2039/505 , C07K16/2809 , C07K2317/24 , C07K2317/622
摘要： The invention provides CD3 specific binding molecules and nucleic acid sequences encoding said CD3 specific binding molecules. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and compositions comprising said construct. The invention also provides the use of said constructs for the preparation of pharmacutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
摘要翻译：本发明提供CD3特异性结合分子和编码所述CD3特异性结合分子的核酸序列。本发明的其它方面是包含所述核酸序列的载体和宿主细胞，用于生产本发明构建体的方法和包含所述构建体的组合物。本发明还提供所述构建体用于制备用于治疗特定疾病的药物组合物，用于治疗特定疾病的方法和包含本发明的结合构建体的试剂盒的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式